A detailed history of Virginia Retirement Systems Et Al transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Virginia Retirement Systems Et Al holds 11,600 shares of DNLI stock, worth $249,283. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,600
Previous 10,400 11.54%
Holding current value
$249,283
Previous $306,000 21.9%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Jan 02, 2024

BUY
$20.63 - $30.17 $24,756 - $36,204
1,200 Added 11.54%
11,600 $239,000
Q2 2023

Aug 22, 2023

SELL
$23.37 - $32.96 $77,121 - $108,768
-3,300 Reduced 24.09%
10,400 $306,000
Q1 2023

Jul 11, 2023

BUY
$21.91 - $32.67 $21,910 - $32,670
1,000 Added 7.87%
13,700 $315,000
Q4 2022

May 17, 2023

SELL
$26.28 - $33.92 $7,884 - $10,176
-300 Reduced 2.31%
12,700 $353 Million
Q3 2022

May 16, 2023

SELL
$25.97 - $38.53 $41,552 - $61,648
-1,600 Reduced 10.96%
13,000 $399 Million
Q1 2022

Apr 21, 2022

SELL
$29.0 - $47.27 $321,900 - $524,697
-11,100 Reduced 43.19%
14,600 $470,000
Q4 2021

Feb 03, 2022

SELL
$42.59 - $55.02 $123,511 - $159,558
-2,900 Reduced 10.14%
25,700 $1.15 Million
Q3 2021

Oct 21, 2021

BUY
$48.48 - $78.23 $310,272 - $500,672
6,400 Added 28.83%
28,600 $1.44 Million
Q2 2021

Aug 13, 2021

BUY
$50.3 - $78.44 $80,480 - $125,504
1,600 Added 7.77%
22,200 $1.74 Million
Q1 2021

Apr 30, 2021

BUY
$53.8 - $81.53 $796,240 - $1.21 Million
14,800 Added 255.17%
20,600 $1.18 Million
Q4 2020

Feb 16, 2021

SELL
$36.89 - $93.56 $298,809 - $757,836
-8,100 Reduced 58.27%
5,800 $486,000
Q3 2020

Nov 12, 2020

BUY
$23.13 - $38.84 $321,507 - $539,876
13,900 New
13,900 $498,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.